PURCHASE AGREEMENT by and between ONCOBIOLOGICS, Inc. and BIOLEXIS PTE. LIMITED Dated November 5, 2018Purchase Agreement • November 9th, 2018 • Oncobiologics, Inc. • Biological products, (no disgnostic substances) • New York
This PURCHASE AGREEMENT (this “Agreement”), dated as of November 5, 2018, is entered into by and between Oncobiologics, Inc., a Delaware corporation (the “Company”), and BioLexis Pte. Limited, a Singapore private limited company (“Investor”).
THIRD AMENDMENT TO INVESTOR RIGHTS AGREEMENTInvestor Rights Agreement • November 9th, 2018 • Oncobiologics, Inc. • Biological products, (no disgnostic substances)
This THIRD AMENDMENT, dated as of November 5, 2018 (this “Amendment”), to the Investor Rights Agreement, dated as of September 11, 2017 (as it may be amended from time to time, the “Investor Rights Agreement”), is entered into between Oncobiologics, Inc., a Delaware corporation (the “Company”), and BioLexis Pte. Limited, a Singapore private limited company (formerly known as GMS Tenshi Holdings Pte. Limited, the “Investor” and, collectively with the Company, the “Parties”). Capitalized terms used but not defined herein shall have the meanings ascribed to them in the Investor Rights Agreement.
